Protein C activated - Kaketsuken/Teijin

Drug Profile

Protein C activated - Kaketsuken/Teijin

Alternative Names: Activated protein C - Kaketsuken/Teijin; Anact C; CTC-111

Latest Information Update: 21 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kaketsuken; Teijin Pharma
  • Developer Teijin Pharma
  • Class Anticoagulants; Antithrombotics; Biological factors; Blood proteins; Enzyme precursors; Glycoproteins
  • Mechanism of Action Protein C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Disseminated intravascular coagulation

Highest Development Phases

  • Marketed Deep vein thrombosis; Disseminated intravascular coagulation; Pulmonary embolism

Most Recent Events

  • 31 Jul 2001 Launched for Pulmonary embolism in Japan (IV)
  • 31 Jul 2001 Launched for Disseminated intravascular coagulation in Japan (IV)
  • 31 Jul 2001 Launched for Thrombosis in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top